analytical procedure development

bring ideas to life – for a better health worldwide Radiopharmaceuticals CDMO / CMOProducts See what makes the Difference Radelumin® is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: • Primary staging of patients with high-risk PCa prior to primary curative therapy• Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.More Radiopharmaceutical Partner from Development to Global Supply ABX is a trusted partner in radiopharmaceutical innovation, combining 30 years of experience with expertise across development, manufacturing, regulatory support and global supply. Our integrated portfolio of radiopharmaceuticals, CDMO / CMO services and products helps bring.

Read more

global distributionGMP manufacturingproject managementQC method developmentradiolabelingradiopharmaceutical developmentregulatory supporttech transfer